Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study.

ABSTRACT: Since 2004, patients receiving imatinib with relapse in non-marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor recognized, we undertook a retrospective observational study of all reported patients with EML given dasatinib ± routine therapies used over 50 years. We elicited remission durations from authors. One hundred and sixty-three patients (150 Ph'+, 13 Ph'- negative leukemias) received dasatinib ± conventional EML treatments. All but six cases reported disappearance of EML involvement, documented by MRI, CSF, PET/CT in 10, and autopsy in 2. To date, 36 EML rem

SUBMITTER: Cunningham I 

PROVIDER: S-EPMC12861714 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature